Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses.

BACKGROUND: Interferon-α/ribavirin combination therapy might promote hepatitis B surface antigen (HBsAg) seroclearance in patients dually infected with hepatitis B and C viruses (HBV/HCV), but the long-term effect remains unclear. We aimed to investigate the rate of and the factors associated with H...

Full description

Bibliographic Details
Main Authors: Ming-Lun Yeh, Chao-Hung Hung, Jee-Fu Huang, Chun-Jen Liu, Chuan-Mo Lee, Chia-Yen Dai, Jing-Houng Wang, Zu-Yau Lin, Sheng-Nan Lu, Tsung-Hui Hu, Ming-Lung Yu, Jia-Horng Kao, Wan-Long Chuang, Pei-Jer Chen, Ding-Shinn Chen
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3113900?pdf=render
id doaj-00f843a9414842358c828a8acddbe244
record_format Article
spelling doaj-00f843a9414842358c828a8acddbe2442020-11-25T02:15:21ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-01-0166e2075210.1371/journal.pone.0020752Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses.Ming-Lun YehChao-Hung HungJee-Fu HuangChun-Jen LiuChuan-Mo LeeChia-Yen DaiJing-Houng WangZu-Yau LinSheng-Nan LuTsung-Hui HuMing-Lung YuJia-Horng KaoWan-Long ChuangPei-Jer ChenDing-Shinn ChenBACKGROUND: Interferon-α/ribavirin combination therapy might promote hepatitis B surface antigen (HBsAg) seroclearance in patients dually infected with hepatitis B and C viruses (HBV/HCV), but the long-term effect remains unclear. We aimed to investigate the rate of and the factors associated with HBsAg seroclearance during long-term follow-up after interferon-α/ribavirin combination therapy in HBV/HCV dually-infected patients. METHODOLOGY/PRINCIPAL FINDINGS: Eighty-one patients who received interferon-α/ribavirin combination therapy for 24 weeks with a follow-up period of >24 weeks were enrolled. HBV serological markers and HBV DNA were determined every 6 months. Early and late HBsAg seroclearance were defined as HBsAg loss in less or more than 6 months after end-of-treatment, respectively. Fifteen (18.5%) patients had HBsAg seroclearance during a mean follow-up period of 3.4 (0.5-5.1) years. The 5-year cumulative incidence was 25.6%. Baseline cirrhosis and HBV DNA negativity 1 year after end-of-treatment were independently predictive of HBsAg seroclearance with an odds ratio (OR), 95% confidence intervals (CI) of 16.6, 1.8-153 and 9.2, 1.4-62.1, respectively, by Cox regression hazard analysis. Four patients developed early and 11 developed late HBsAg seroclearance, respectively. Cox regression hazard analysis showed no factor was associated with early HBsAg seroclearance, whilst HBV DNA negativity 1 year after end-of-treatment was the only significant factor predicting late HBsAg loss (OR, 43.0; CI, 2.5-745). Five patients had HBsAg seroconversion with a 5-year cumulative incidence of 8.3%. HBV DNA negativity at baseline and one year after EOT had a trend for HBsAg seroconversion. HCV response did not correlate to HBsAg loss. CONCLUSIONS: We demonstrated that interferon-α/ribavirin had long-term effect on HBsAg seroclearance in dually HBV/HCV-infected patients. Baseline cirrhosis and seroclearance of HBV DNA 1 year after end-of-treatment were significant factors associated with HBsAg seroclearance.http://europepmc.org/articles/PMC3113900?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Ming-Lun Yeh
Chao-Hung Hung
Jee-Fu Huang
Chun-Jen Liu
Chuan-Mo Lee
Chia-Yen Dai
Jing-Houng Wang
Zu-Yau Lin
Sheng-Nan Lu
Tsung-Hui Hu
Ming-Lung Yu
Jia-Horng Kao
Wan-Long Chuang
Pei-Jer Chen
Ding-Shinn Chen
spellingShingle Ming-Lun Yeh
Chao-Hung Hung
Jee-Fu Huang
Chun-Jen Liu
Chuan-Mo Lee
Chia-Yen Dai
Jing-Houng Wang
Zu-Yau Lin
Sheng-Nan Lu
Tsung-Hui Hu
Ming-Lung Yu
Jia-Horng Kao
Wan-Long Chuang
Pei-Jer Chen
Ding-Shinn Chen
Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses.
PLoS ONE
author_facet Ming-Lun Yeh
Chao-Hung Hung
Jee-Fu Huang
Chun-Jen Liu
Chuan-Mo Lee
Chia-Yen Dai
Jing-Houng Wang
Zu-Yau Lin
Sheng-Nan Lu
Tsung-Hui Hu
Ming-Lung Yu
Jia-Horng Kao
Wan-Long Chuang
Pei-Jer Chen
Ding-Shinn Chen
author_sort Ming-Lun Yeh
title Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses.
title_short Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses.
title_full Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses.
title_fullStr Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses.
title_full_unstemmed Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses.
title_sort long-term effect of interferon plus ribavirin on hepatitis b surface antigen seroclearance in patients dually infected with hepatitis b and c viruses.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2011-01-01
description BACKGROUND: Interferon-α/ribavirin combination therapy might promote hepatitis B surface antigen (HBsAg) seroclearance in patients dually infected with hepatitis B and C viruses (HBV/HCV), but the long-term effect remains unclear. We aimed to investigate the rate of and the factors associated with HBsAg seroclearance during long-term follow-up after interferon-α/ribavirin combination therapy in HBV/HCV dually-infected patients. METHODOLOGY/PRINCIPAL FINDINGS: Eighty-one patients who received interferon-α/ribavirin combination therapy for 24 weeks with a follow-up period of >24 weeks were enrolled. HBV serological markers and HBV DNA were determined every 6 months. Early and late HBsAg seroclearance were defined as HBsAg loss in less or more than 6 months after end-of-treatment, respectively. Fifteen (18.5%) patients had HBsAg seroclearance during a mean follow-up period of 3.4 (0.5-5.1) years. The 5-year cumulative incidence was 25.6%. Baseline cirrhosis and HBV DNA negativity 1 year after end-of-treatment were independently predictive of HBsAg seroclearance with an odds ratio (OR), 95% confidence intervals (CI) of 16.6, 1.8-153 and 9.2, 1.4-62.1, respectively, by Cox regression hazard analysis. Four patients developed early and 11 developed late HBsAg seroclearance, respectively. Cox regression hazard analysis showed no factor was associated with early HBsAg seroclearance, whilst HBV DNA negativity 1 year after end-of-treatment was the only significant factor predicting late HBsAg loss (OR, 43.0; CI, 2.5-745). Five patients had HBsAg seroconversion with a 5-year cumulative incidence of 8.3%. HBV DNA negativity at baseline and one year after EOT had a trend for HBsAg seroconversion. HCV response did not correlate to HBsAg loss. CONCLUSIONS: We demonstrated that interferon-α/ribavirin had long-term effect on HBsAg seroclearance in dually HBV/HCV-infected patients. Baseline cirrhosis and seroclearance of HBV DNA 1 year after end-of-treatment were significant factors associated with HBsAg seroclearance.
url http://europepmc.org/articles/PMC3113900?pdf=render
work_keys_str_mv AT minglunyeh longtermeffectofinterferonplusribavirinonhepatitisbsurfaceantigenseroclearanceinpatientsduallyinfectedwithhepatitisbandcviruses
AT chaohunghung longtermeffectofinterferonplusribavirinonhepatitisbsurfaceantigenseroclearanceinpatientsduallyinfectedwithhepatitisbandcviruses
AT jeefuhuang longtermeffectofinterferonplusribavirinonhepatitisbsurfaceantigenseroclearanceinpatientsduallyinfectedwithhepatitisbandcviruses
AT chunjenliu longtermeffectofinterferonplusribavirinonhepatitisbsurfaceantigenseroclearanceinpatientsduallyinfectedwithhepatitisbandcviruses
AT chuanmolee longtermeffectofinterferonplusribavirinonhepatitisbsurfaceantigenseroclearanceinpatientsduallyinfectedwithhepatitisbandcviruses
AT chiayendai longtermeffectofinterferonplusribavirinonhepatitisbsurfaceantigenseroclearanceinpatientsduallyinfectedwithhepatitisbandcviruses
AT jinghoungwang longtermeffectofinterferonplusribavirinonhepatitisbsurfaceantigenseroclearanceinpatientsduallyinfectedwithhepatitisbandcviruses
AT zuyaulin longtermeffectofinterferonplusribavirinonhepatitisbsurfaceantigenseroclearanceinpatientsduallyinfectedwithhepatitisbandcviruses
AT shengnanlu longtermeffectofinterferonplusribavirinonhepatitisbsurfaceantigenseroclearanceinpatientsduallyinfectedwithhepatitisbandcviruses
AT tsunghuihu longtermeffectofinterferonplusribavirinonhepatitisbsurfaceantigenseroclearanceinpatientsduallyinfectedwithhepatitisbandcviruses
AT minglungyu longtermeffectofinterferonplusribavirinonhepatitisbsurfaceantigenseroclearanceinpatientsduallyinfectedwithhepatitisbandcviruses
AT jiahorngkao longtermeffectofinterferonplusribavirinonhepatitisbsurfaceantigenseroclearanceinpatientsduallyinfectedwithhepatitisbandcviruses
AT wanlongchuang longtermeffectofinterferonplusribavirinonhepatitisbsurfaceantigenseroclearanceinpatientsduallyinfectedwithhepatitisbandcviruses
AT peijerchen longtermeffectofinterferonplusribavirinonhepatitisbsurfaceantigenseroclearanceinpatientsduallyinfectedwithhepatitisbandcviruses
AT dingshinnchen longtermeffectofinterferonplusribavirinonhepatitisbsurfaceantigenseroclearanceinpatientsduallyinfectedwithhepatitisbandcviruses
_version_ 1724897161520349184